Addex to Present at 25th Annual BIO-Europe Conference in Hamburg

Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program

Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update

ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019

ADDEX THERAPEUTICS SUBMITS REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES

Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share

Addex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Annual General Meeting Scheduled for June 19, 2019

Addex Increases Issued Share Capital and Creates Treasury Shares